Somatostatin receptor SPECT
- PMID: 22388628
- DOI: 10.1007/s00259-011-2019-2
Somatostatin receptor SPECT
Abstract
Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.
Comment in
-
Comment on Pepe et al.: somatostatin receptor SPECT.Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1656-7. doi: 10.1007/s00259-012-2147-3. Epub 2012 May 30. Eur J Nucl Med Mol Imaging. 2012. PMID: 22644712 Free PMC article. No abstract available.
Similar articles
-
Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.PET Clin. 2014 Jan;9(1):11-26. doi: 10.1016/j.cpet.2013.08.011. Epub 2013 Oct 4. PET Clin. 2014. PMID: 25029930 Review.
-
Tumor imaging and therapy using radiolabeled somatostatin analogues.Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e. Acc Chem Res. 2009. PMID: 19445476
-
Peptide receptor imaging and therapy.J Nucl Med. 2000 Oct;41(10):1704-13. J Nucl Med. 2000. PMID: 11038002 Review.
-
Neuroendocrine tumors and somatostatin: imaging techniques.J Endocrinol Invest. 2005;28(11 Suppl International):132-6. J Endocrinol Invest. 2005. PMID: 16625862 Review.
-
Imaging of neuroendocrine tumors.Semin Nucl Med. 2006 Jul;36(3):228-47. doi: 10.1053/j.semnuclmed.2006.03.007. Semin Nucl Med. 2006. PMID: 16762613 Review.
Cited by
-
The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.Cancers (Basel). 2023 Dec 25;16(1):116. doi: 10.3390/cancers16010116. Cancers (Basel). 2023. PMID: 38201544 Free PMC article. Review.
-
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.Cancers (Basel). 2023 Jul 4;15(13):3483. doi: 10.3390/cancers15133483. Cancers (Basel). 2023. PMID: 37444593 Free PMC article. Review.
-
Biomarkers in preclinical cancer imaging.Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):579-96. doi: 10.1007/s00259-014-2980-7. Epub 2015 Feb 12. Eur J Nucl Med Mol Imaging. 2015. PMID: 25673052 Free PMC article. Review.
-
Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics.Molecules. 2018 Dec 23;24(1):49. doi: 10.3390/molecules24010049. Molecules. 2018. PMID: 30583594 Free PMC article. Review.
-
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging.Pharmaceuticals (Basel). 2020 Mar 3;13(3):38. doi: 10.3390/ph13030038. Pharmaceuticals (Basel). 2020. PMID: 32138377 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources